O Serviço Psiquiátrico de Diagnóstico e Tratamento no Hospital Geral: usuários e novas urgências

El Servizio di psichiatrico Diagnosis and Healing (SPDC), que nació como una representación del "territorio" dentro de la realidad del hospital. Objetivos. El objetivo de la investigación es mostrar qué nuevas emergencias en SPDC y cómo estas situaciones han cambiado en el pasado. Tres estudios diferentes se planearon. El primer estudio analizó el principio de los trastornos esquizofrénicos en el primer contacto con los servicios psiquiátricos, para evaluar una posible correlación entre la aparición de la esquizofrenia y el abuso de sustancias de 136 pacientes ingresados en el Consejo de Estado, en el período comprendido entre 2001 y 2007. El segundo estudio evaluó retrospectivamente a partir de 1985 a 1998, comparándolos con los del trienio 2007-2009. Y por último, el tercer estudio midió la tasa de agotamiento de casi todos los operadores de casi todos piamonteses SPDC. En todos los estudios publicados, las escalas psicopatológicas se han utilizado y reconocido pruebas. En 130 episodios esquizofrénicos, el 46,1% tiene una anamnesis positiva para el abuso de sustancias. Estos pacientes muestran una mayor resistencia al tratamiento inicial con hospitalizaciones más largas. El análisis mostró alteraciones, a través de los años, una reducción en las hospitalizaciones por psicosis esquizofrénica, lo que contrasta con un aumento en las hospitalizaciones por trastornos de la personalidad y agitación psicomotora. El análisis de las tasas de agotamiento, la mayoría de los operadores tienen valores medio-alto agotamiento emocional y despersonalización, mientras que el 47% tiene baja realización personal. Estas condiciones psicopatológicas casi siempre se asocia con una mayor carga para la asistencia social que se refleja operadores con el mismo riesgo de burnout

Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel

Background: Treatment-resistant depression (TRD) is defined by the European Medicines Agency as a lack of clinically meaningful improvement after treatment, with at least two different antidepressants. Individual, familiar, and socio-economic burden of TRD is huge. Given the lack of clear guidelines, the large variability of TRD approaches across different countries and the availability of new medications to meet the need of effective and rapid acting therapeutic strategies, it is important to understand the consensus regarding the clinical characteristics and treatment pathways of patients with TRD in Italian routine clinical practice, particularly in view of the recent availability of esketamine nasal spray. Methods: A Delphi questionnaire with 17 statements (with a 7 points Likert scale for agreement) was administered via a customized web-based platform to Italian psychiatrists with at least 5 years of experience and specific expertise in the field of depression. In the second-round physicians were asked to answer the same statements considering the interquartile range of each question as an index of their colleagues' responses. Stata 16.1 software was used for the analyses. Results: Sixty panellists, representative of the Italian territory, answered the questionnaire at the first round. For 8/17 statements more than 75% of panellists reached agreement and a high consensus as they assigned similar scores; for 4 statements the panellists assigned similar scores but in the middle of the Likert scale showing a moderate agreement with the statement, while for 5 statements there was indecision in the agreement and low consensus with the statement. Conclusions: This Delphi Panel showed that there is a wide heterogeneity in Italy in the management of TRD patients, and a compelling need of standardised strategies and treatments specifically approved for TRD. A high level of consensus and agreement was obtained about the importance of adding lithium and/or antipsychotics as augmentation therapies and in the meantime about the need for long-term maintenance therapy. A high level of consensus and agreement was equally reached for the identification of esketamine nasal spray as the best option for TRD patients and for the possibility to administrate without difficulties esketamine in a community outpatient setting, highlighting the benefit of an appropriate educational support for patients

Impact of menstrual cycle events on bipolar disorder course: a narrative review of current evidence

Several lines of research suggest that reproductive-related hormonal events may affect the course of bipolar disorder in some women. However, data on associations between bipolar disorder and menarche, menstrual cycle, and menopause are mixed. This article reviews the literature on the potential effects of menarche, menstrual cycle, and menopause on bipolar disorder. A narrative review of published articles on bipolar disorder and menstrual cycle events was conducted. The primary outcome assessed was the impact of menarche, menstrual cycle and menopause on the course of bipolar illness. Databases searched were PubMed, Ovid, Scopus, PsycINFO, Medline, and Cochrane Libraries from inception to August 2021.Twenty-two studies were identified and included in the narrative synthesis. Research suggested that a subset of women with bipolar disorder are vulnerable to the impact of menstrual cycle events. Menarche seems to be associated with age at onset of bipolar illness especially in case of bipolar disorder type I and the specific age at menarche may predict some clinical features of the disorder. Menstrual cycle likely affects the course of bipolar disorder but the pattern of mood variability is not clear. Menopause appears to be not only a period of vulnerability to mood alteration, especially depressive episodes, and impairment of quality of life, but also a potential trigger of bipolar illness onset.The impact of menarche, menstrual cycle, and menopause on bipolar disorder is largely understudied. Preliminary evidence suggests that a subset of women with bipolar disorder may have their mood shifts affected by menstrual cycle events, with different patterns depending on the type of bipolar disorder also. Further researches are needed to deep the impact of menarche, menstrual cycle, and menopause on bipolar illness